Abstract
Background Chest CT (CT) is the reference for assessing pulmonary injury in suspected or diagnosed COVID-19 with signs of clinical severity. We explored the role of lung ultrasonography (LU) in quickly assessing lung status in these patients.
Methods eChoVid is a multicentric study based on routinely collected data, conducted in 3 emergency units of Assistance Publique des Hôpitaux de Paris (APHP); 107 patients were included between March 19, 2020 and April 01, 2020 and underwent LU, a short clinical assessment by 2 emergency physicians blinded to each other’s and a CT. LU consisted of scoring lesions in 8 chest zones from 0 to 3, defining a severity global score (GS) ranging from 0 to 24. CT severity score ranged from 0 to 3 according to the extent of interstitial pneumonia signs. 48 patients underwent LU by both an expert and a newly trained physician.
Findings The GS showed good performance to predict CT severity assessment of COVID-19 as normal versus pathologic: AUC=0.93, maximal Youden index 1 with 95% sensitivity, and 83% specificity. Similar performance was found for CT assessment as normal or minimal versus moderate or severe (n=90): AUC 0.89, maximal Youden index 7 with 86% sensitivity, and 78% specificity. Good agreement was found for zone scoring assessed by new trainee (30mn theory + 30mn practice) and expert (n=14,14*8 checkpoints), weighted kappa 0.85-1; moderate agreement was found for new trainee (n=48, 30mn theory) and expert, kappa 0.62-0.81.
Interpretation GS score is a simple tool to assess lung damage severity in patients with suspected or diagnosed COVID-19. Comparing the performance of new trainees and expert physicians opens a path for adoption beyond the scope of experts. LU is a good candidate for patients triage, especially in case of CT availability issues.
Competing Interest Statement
Dr Mehdi Benchoufi reports other from echOpen factory, he is the co-founder of echopen factory, and has equity in the company. echOpen factory is developing accessible handheld ultrasound device in open source (software and hardware) and in low-cost. Outside the submitted work, he is the co-founder of echOpen association, developing with a global community handheld ultrasound research tools in open source (software and hardware). Dr Marie-Laure Baranne reports other from echOpen factory, she has equity in the company. Outside the submitted work; she is a member of the echOpen association, developing with a global community handheld ultrasound research tools in open source (software and hardware). Dr Sylvain Benenati reports non-financial support from SONOSITE-FUJIFILM, other from SONOSITE-FUJIFILM, outside the submitted work. Dr Mikaël Martinez: Dr. Martinez reports personal fees from Astra Zeneca, outside the submitted work. Dr Jerôme Bokobza, Dr Anthony Chauvin, Pr Elisabeth Dion, Dr Fabien Levan, Dr Maxime Gautier, Dr Delphine Cantin, Dr Thomas d’Humières, Dr Cédric Gil-Jardiné, Dr Sylvain Benenati, Dr Mathieu Orbelin, Dr Nathalie Pierre-Kahn, Abdourahmane Diallo, Pr Eric Vicaut have nothing to disclose. Dr Pierre Bourrier reports other from echOpen factory, he has equity in the company. Outside the submitted work; she is a member of the echOpen association, developing with a global community handheld ultrasound research tools in open source (software and hardware)
Funding Statement
At the moment of the writing, no funding have been obtained. Funding have been resquested from the INNOVARC public intiative*. Authors did not receive an answer yet. https://solidarites-sante.gouv.fr/systeme-de-sante-et-medico-social/recherche-et-innovation/l-innovation-et-la-recherche-clinique/appels-a-projets/innovarc
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
On behalf of the AP-HP / Universities / Inserm COVID-19 research collaboration
Data Availability
At this time, the data is still not freely available.
